Protagenic Therapeutics (PTIX) warns Q2 2026 10-Q will miss extension window

Rhea-AI Filing Summary

Protagenic Therapeutics, Inc. notified the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 by the prescribed due date without unreasonable effort or expense. The company is working to complete the remaining items but does not expect to file the Form 10-Q within the five-day extension period provided by Rule 12b-25.

Key Terms

Rule 12b-25, Quarterly Report on Form 10-Q, significant change in results of operations

3 terms

Rule 12b-25 regulatory

"the five-day extension period provided by Rule 12b-25"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Quarterly Report on Form 10-Q regulatory

"file its Quarterly Report on Form 10-Q for the period ended June 30, 2026"

A quarterly report on Form 10-Q is a standardized financial filing public companies must submit to U.S. regulators every three months, summarizing recent financial results, cash flows, balance sheet changes, operations and material risks or legal developments. Investors treat it like a company report card that shows up-to-date facts rather than marketing copy, helping them track performance, spot trends, reassess risk and make buy or sell decisions.

significant change in results of operations financial

"Is it anticipated that any significant change in results of operations"

FAQ

Why did Protagenic Therapeutics (PTIX) file an NT 10-Q?

Protagenic Therapeutics filed an NT 10-Q because it cannot complete its Quarterly Report for June 30, 2026 by the prescribed due date without unreasonable effort or expense. The company is still working to finalize remaining items.

Which period does Protagenic Therapeutics’ delayed Form 10-Q cover?

The delayed Form 10-Q for Protagenic Therapeutics covers the quarter ended June 30, 2026. The company states it cannot file this report on time and is still completing remaining work.

Will Protagenic Therapeutics (PTIX) file its 10-Q within the Rule 12b-25 extension?

Protagenic Therapeutics does not expect to file its Form 10-Q within the five-day extension period provided by Rule 12b-25, even though it is working to complete the report as promptly as practicable.

What rule is Protagenic Therapeutics using to notify of its late 10-Q?

The company is using Rule 12b-25 to notify regulators and investors that its Form 10-Q for June 30, 2026 will be filed late, citing unreasonable effort or expense to meet the original deadline.

Who signed Protagenic Therapeutics’ NT 10-Q notification?

The notification was signed on behalf of Protagenic Therapeutics by Garo H. Armen, PhD, who serves as Principal Executive Officer and Principal Financial Officer, indicating executive-level acknowledgment of the delayed filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 03:20 PM Accepted by SEC EDGAR 08/14/2026 - 03:20 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-SAR  ☐ Form N-CSR

For Period Ended: June 30, 2026

	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q
	☐	Transition Report on Form N-SAR

For the Transition Period Ended: _____________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Protagenic Therapeutics, Inc.

Full Name of Registrant

Atrinsic, Inc.

Former Name if Applicable

149 Fifth Ave, Suite 500

Address of Principal Executive Office (Street and Number)

New York, NY 10010

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☒	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
☐	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Protagenic Therapeutics, Inc. (the “Company”) will not be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 by the prescribed due date without unreasonable effort or expense.

The Company is working to complete the remaining items as promptly as practicable but does not expect to file the Form 10-Q within the five-day extension period provided by Rule 12b-25.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Garo H. Armen, PhD, Principal Executive Officer and Principal Financial Officer		212		994-8200
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Protagenic Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

	PROTAGENIC THERAPEUTICS, INC.
Date: August 14, 2026	By:	/s/ Garo H. Armen, PhD.
	Name:	Garo H. Armen, PhD.
	Title:	Principal Executive Officer and Principal Financial Officer